Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Neuropharmacology

• Publication date

  2004-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/J.NEUROPHARM.2004.07.040PMID 15555642
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Long-term potentiation and memory.

  2004cited by this paper
• Forskolin-induced LTP in the CA1 hippocampal region is NMDA receptor dependent.

  2004cited by this paper
• Effects of two selective phosphodiesterase type 5 inhibitors, sildenafil and vardenafil, on object recognition memory and hippocampal cyclic GMP levels in the rat.

  2002cited by this paper
• cGMP and S-nitrosylation: two routes for modulation of neuronal excitability by NO.

  2002cited by this paper
• Kinetics of nitric oxide‐cyclic GMP signalling in CNS cells and itspossible regulation by cyclic GMP

  2002cited by this paper
• cGMP, but not cAMP, in rat hippocampus is involved in early stages of object memory consolidation.

  2002cited by this paper
• β-Amyloid Peptides Decrease Soluble Guanylyl Cyclase Expression in Astroglial Cells

  2002cited by this paper
• Hydrolysis of N-methyl-D-aspartate receptor-stimulated cAMP and cGMP by PDE4 and PDE2 phosphodiesterases in primary neuronal cultures of rat cerebral cortex and hippocampus.

  2002cited by this paper
• Pharmacological actions of a novel NO‐independent guanylyl cyclase stimulator, BAY 41‐8543: in vitro studies

  2002cited by this paper
• Long-Term Potentiation in Hippocampus Involves Sequential Activation of Soluble Guanylate Cyclase, cGMP-Dependent Protein Kinase, and cGMP-Degrading Phosphodiesterase

  2002cited by this paper
• NMDA receptors and learning and memory processes.

  2001cited by this paper
• Nerve growth factor inhibits PC12 cell PDE 2 phosphodiesterase activity and increases PDE 2 binding to phosphoproteins

  2001cited by this paper
• The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil

  2001cited by this paper
• Presynaptic Role of cGMP-Dependent Protein Kinase during Long-Lasting Potentiation

  2001cited by this paper
• The effects of phosphodiesterase inhibition on cyclic GMP and cyclic AMP accumulation in the hippocampus of the rat.

  2001cited by this paper
• Reduced [3H]cGMP binding in brain staged for Alzheimer's disease pathologies

  2000cited by this paper
• William Harvey Research Conference on PDE inhibitors: drugs with an expanding range of therapeutic uses

  2000cited by this paper
• Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions.

  2000cited by this paper
• Effects of sildenafil on long-term retention of an inhibitory avoidance response in mice.

  1999cited by this paper
• Nitric Oxide Signaling Contributes to Late-Phase LTP and CREB Phosphorylation in the Hippocampus

  1999cited by this paper
• Nitric oxide as a retrograde messenger during long-term potentiation in hippocampus.

  1998cited by this paper
• When Are Class I Metabotropic Glutamate Receptors Necessary for Long-Term Potentiation?

  1998cited by this paper
• The 5-HT1A receptor agonist BAY x 3702 prevents staurosporine-induced apoptosis.

  1998cited by this paper
• Probing the active site of adenosine deaminase by a pH responsive fluorescent competitive inhibitor.

  1998cited by this paper
• Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3',5'-cyclic nucleotide phosphodiesterase.

  1998cited by this paper
• A new continuous alternation task in T-maze detects hippocampal dysfunction in mice. A strain comparison and lesion study.

  1998cited by this paper
• Cyclic GMP‐Dependent Protein Kinase and Cellular Signaling in the Nervous System

  1997cited by this paper
• Analysis of the ligand binding site of the 5-HT3 receptor using site directed mutagenesis: importance of glutamate 106.

  1997cited by this paper
• Functional and radioligand binding characterization of rat 5-HT6 receptors stably expressed in HEK293 cells.

  1997cited by this paper
• The Serotonin 5‐HT2C Receptor Is a Prominent Serotonin Receptor in Basal Ganglia: Evidence from Functional Studies on Serotonin‐Mediated Phosphoinositide Hydrolysis

  1997cited by this paper
• Nitric oxide, the enigmatic neuronal messenger: its role in synaptic plasticity.

  1997cited by this paper
• Possible role of nitric oxide-cyclic GMP pathway in object recognition memory: effects of 7-nitroindazole and zaprinast.

  1997cited by this paper
• Cyclic-nucleotide-gated channels mediate synaptic feedback by nitric oxide

  1997cited by this paper
• Long-term potentiation is reduced in mice that are doubly mutant in endothelial and neuronal nitric oxide synthase.

  1996cited by this paper
• Pharmacological and biochemical characterization of purified A2a adenosine receptors in human platelet membranes by [3H]‐CGS 21680 binding

  1996cited by this paper
• Hippocampal cGMP and cAMP are differentially involved in memory processing of inhibitory avoidance learning

  1996cited by this paper
• Role of nitric oxide and cyclic GMP in the dizocilpine-induced impairment of spontaneous alternation behavior in mice.

  1996cited by this paper
• Memories of NMDA receptors and LTP

  1995cited by this paper
• Activity-dependent long-term enhancement of transmitter release by presynaptic 3′,5′-cyclic GMP in cultured hippocampal neurons

  1995cited by this paper
• Nitric oxide-dependent long-term potentiation is blocked by a specific inhibitor of soluble guanylyl cyclase.

  1995cited by this paper
• Isozyme selective inhibition of cGMP-stimulated cyclic nucleotide phosphodiesterases by erythro-9-(2-hydroxy-3-nonyl) adenine.

  1995cited by this paper
• The pharmacology and distribution of human 5‐hydroxytryptamine2B (5‐HT2b) receptor gene products: comparison with 5‐HT2a and 5‐HT2c receptors

  1995cited by this paper
• Reduced nitric oxide responsive soluble guanylyl cyclase activity in the superior temporal cortex of patients with Alzheimer's disease.

  1995cited by this paper
• Role of guanylyl cyclase and cGMP-dependent protein kinase in long-term potentiation

  1994cited by this paper
• Adenosine deaminase inhibitors. Synthesis and biological evaluation of putative metabolites of (+)-erythro-9-(2S-hydroxy-3R-nonyl)adenine.

  1994cited by this paper
• Receptors for 5-hydroxytryptamine: current perspectives on classification and nomenclature.

  1994cited by this paper
• Binding characteristics of a histamine H3-receptor antagonist, [3H]S-methylthioperamide: comparison with [3H](R)alpha-methylhistamine binding to rat tissues.

  1994cited by this paper
• Extracellular cGMP in the hippocampus of freely moving rats as an index of nitric oxide (NO) synthase activity

  1994cited by this paper
• Expression of Soluble Guanylyl Cyclase Gene in Adult Rat Brain

  1994cited by this paper
• Inhibiting synthesis of the putative retrograde messenger nitric oxide results in amnesia in a passive avoidance task in the chick.

  1993cited by this paper
• Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype.

  1993cited by this paper
• Genomic cloning, heterologous expression and pharmacological characterization of a human histamine H1 receptor.

  1993cited by this paper
• Development of a radioligand binding assay for 5‐HT4 receptors in guinea‐pig and rat brain

  1993cited by this paper
• A cyclic GMP-stimulated cyclic nucleotide phosphodiesterase gene is highly expressed in the limbic system of the rat brain.

  1993cited by this paper
• The effect of pralidoxime chloride in the assay of acetylcholinesterase using 5,5'-dithio-bis(2-nitrobenzoic acid) (Ellman's reagent).

  1992cited by this paper
• Cloning and functional characterization of a human A1 adenosine receptor.

  1992cited by this paper
• Localization of adenylyl and guanylyl cyclase in rat brain by in situ hybridization: comparison with calmodulin mRNA distribution

  1992cited by this paper
• On the stimulation of soluble and particulate guanylate cyclase in the rat brain and the involvement of nitric oxide as studied by cGMP immunocytochemistry.

  1992cited by this paper
• Glutamate, nitric oxide and cell-cell signalling in the nervous system.

  1991cited by this paper
• Comparative membrane locations and activities of human monoamine oxidases expressed in yeast

  1991cited by this paper
• Nitric oxide synthase protein and mRNA are discretely localized in neuronal populations of the mammalian CNS together with NADPH diaphorase.

  1991cited by this paper
• Tests of the roles of two diffusible substances in long-term potentiation: evidence for nitric oxide as a possible early retrograde messenger.

  1991cited by this paper
• A requirement for the intercellular messenger nitric oxide in long-term potentiation.

  1991cited by this paper
• Possible involvement of nitric oxide in long-term potentiation.

  1991cited by this paper
• [3H]CGP 39653: a new N-methyl-D-aspartate antagonist radioligand with low nanomolar affinity in rat brain.

  1991cited by this paper
• Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells.

  1989cited by this paper
• A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data.

  1988cited by this paper
• [3H]AMPA binding to glutamate receptor subpopulations in rat brain.

  1987cited by this paper
• [3H]Muscimol Binding Site on Purified Benzodiazepine Receptor

  1983cited by this paper
• Purification and characterization of a cyclic GMP-stimulated cyclic nucleotide phosphodiesterase from bovine tissues.

  1982cited by this paper
• Social memory of the male laboratory rat.

  1982cited by this paper
• Specific binding of [3H]kainic acid to receptor sites in rat brain.

  1979cited by this paper
• Benzodiazepine receptors: temperature dependence of [3H]flunitrazepam binding.

  1979cited by this paper

• Discovery of novel 2,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridine-7-one derivatives as PDE2 inhibitors with Alzheimer's disease therapeutic potential.

  2025cites this paper
• The impact of response latency on working memory assessment in mice.

  2025cites this paper
• Mechanistic insights into the identification of Phosphodiesterase 2 inhibitors from acridine analogues

  2025cites this paper
• Navigating the treatment landscape of Alzheimer's disease: Current strategies and future directions

  2025cites this paper
• Identify natural compounds as novel phosphodiesterase-2A inhibitors.

  2025cites this paper
• Cyclic nucleotide phosphodiesterases as drug targets.

  2025cites this paper
• Cyclic Nucleotide Phosphodiesterase Families as Targets to Treat Pulmonary Arterial Hypertension: Beyond PDE5 Inhibitors?

  2025influential citation
• Longevity, enhanced memory, and altered density of dendritic spines in hippocampal CA3 and dentate gyrus after hemizygous deletion of Pde2a in mice

  2024influential citation
• Effects of the phosphodiesterase 2 inhibitor BI 474121 on central nervous system cyclic guanosine monophosphate concentrations: Translational studies

  2024cites this paper
• Ca2+-dependent phosphodiesterase 1 regulates the plasticity of striatal spiny projection neuron glutamatergic synapses

  2024cites this paper
• Propranolol attenuates the establishment of conditioned context aversions: differential effects compared to MK-801 in an animal model of anticipatory nausea and vomiting

  2024cites this paper
• Phosphodiesterase 2 (PDE2) inhibitors: an updated patent review (2017–present)

  2024cites this paper
• PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF ALZHEIMER'S DISEASE

  2024cites this paper
• Optogenetic elevation of postsynaptic cGMP in the hippocampal dentate gyrus enhances LTP and modifies mouse behaviors

  2024cites this paper
• Phosphodiesterases, 3',5'-cyclic nucleotide (PDEs) in GtoPdb v.2023.1

  2023cites this paper
• CNP Promotes Antiarrhythmic Effects via Phosphodiesterase 2

  2023cites this paper
• Dysfunctional mitochondrial processes contribute to energy perturbations in the brain and neuropsychiatric symptoms

  2023cites this paper
• Defects in AMPAR trafficking and microglia activation underlie socio-cognitive deficits associated to decreased expression of Phosphodiesterase 2A

  2023cites this paper
• Phosphodiesterase 2 and Its Isoform a as Therapeutic Targets in the Central Nervous System Disorders.

  2023cites this paper
• Long-Timescale Simulations Revealed Critical Non-Conserved Residues of Phosphodiesterases Affecting Selectivity of BAY60-7550

  2022cites this paper
• Current Drug Targets in Alzheimer's Associated Memory Impairment: A Comprehensive Review.

  2022cites this paper
• An exit beyond the pharmacophore model for 5-HT6R agents - a new strategy to gain dual 5-HT6/5-HT2A action for triazine derivatives with procognitive potential.

  2022cites this paper
• Design and Synthesis of PDE2A Inhibitors for the Treatment of Parkinson's Disease

  2022cites this paper
• Subacute and chronic proteomic and phosphoproteomic analyses of a mouse model of traumatic brain injury at two timepoints and comparison with chronic traumatic encephalopathy in human samples

  2022cites this paper
• Radiosynthesis and Preclinical Evaluation of an 18F-Labeled Triazolopyridopyrazine-Based Inhibitor for Neuroimaging of the Phosphodiesterase 2A (PDE2A)

  2022cites this paper
• The Antidepressant-like Activity, Effects on Recognition Memory Deficits, Bioavailability, and Safety after Chronic Administration of New Dual-Acting Small Compounds Targeting Neuropsychiatric Symptoms in Dementia

  2022cites this paper
• Essential role of the mitochondrial Na+/Ca2+ exchanger NCLX in mediating PDE2-dependent neuronal survival and learning

  2022influential citation
• Therapeutic potential of phosphodiesterase inhibitors for cognitive amelioration in Alzheimer's disease.

  2022cites this paper
• Potential role of IP3/Ca2+ signaling and phosphodiesterases: Relevance to neurodegeneration in Alzheimer's disease and possible therapeutic strategies.

  2022cites this paper
• Phosphodiesterase 2A inhibition corrects the aberrant behavioral traits observed in genetic and environmental preclinical models of Autism Spectrum Disorder

  2022cites this paper
• The Medicinal Chemistry of Caffeine.

  2021cites this paper
• Pivotal role of phosphodiesterase 10A in the integration of dopamine signals in mice striatal D1 and D2 medium‐sized spiny neurones

  2021cites this paper
• The mitochondrial Na+/Ca2+ exchanger, NCLX, mediates PDE2 dependent neuronal survival and learning

  2021cites this paper
• Role of phosphodiesterases in the pathophysiology of neurodevelopmental disorders

  2021cites this paper
• The Phenoxyalkyltriazine Antagonists for 5-HT6 Receptor with Promising Procognitive and Pharmacokinetic Properties In Vivo in Search for a Novel Therapeutic Approach to Dementia Diseases

  2021cites this paper
• Phosphodiesterases, 3',5'-cyclic nucleotide (PDEs) in GtoPdb v.2021.3

  2021cites this paper
• PDE inhibition in distinct cell types to reclaim the balance of synaptic plasticity

  2021cites this paper
• The Role of PDE11A4 in Social Isolation-Induced Changes in Intracellular Signaling and Neuroinflammation

  2021cites this paper
• Tadalafil Reversed H-89 – and Scopolamine – Induced Spatial Learning Impairments in Male Rats

  2021cites this paper
• Hippocampal AMPA‐ and NMDA‐induced cGMP signals are mainly generated by NO‐GC2 and are under tight control by PDEs 1 and 2

  2021influential citation
• Pivotal role of PDE10A in the integration of dopamine signals in mice striatal D1 and D2 medium-sized spiny neurones

  2021cites this paper
• Contributions of animal models of cognitive disorders to neuropsychopharmacology.

  2021cites this paper
• Discovery of novel N-1 substituted pyrazolopyrimidinones as potent, selective PDE2 inhibitors.

  2021cites this paper
• Neurobiological Insights into Twice Exceptionality: Circuits, Cells, and Molecules.

  2021cites this paper
• Cyclic nucleotide phosphodiesterase inhibition as a potential therapeutic target in renal ischemia reperfusion injury.

  2021cites this paper
• Antiamnesic effects of tofisopam against scopolamine-induced cognitive impairments in rats.

  2020cites this paper
• Cyclic nucleotide phosphodiesterases: New targets in the metabolic syndrome?

  2020cites this paper
• Role of cyclic nucleotides and their downstream signaling cascades in memory function: being at the right time at the right spot.

  2020cites this paper
• EFFECT OF DROTAVERINE, A PHOSPHODIESTERASE 4 INHIBITOR IN SCOPOLAMINE-INDUCED COGNITIVE IMPAIRMENT IN RATS

  2020cites this paper
• Focus Your Screening Library: Rapid Identification of Novel PDE2 Inhibitors with in silico Driven Library Prioritization and MicroScale Thermophoresis

  2020cites this paper
• The long and winding road of designing phosphodiesterase inhibitors for the treatment of heart failure.

  2020cites this paper
• Pharmacological inhibition of Phosphodiesterase 7 enhances consolidation processes of spatial memory.

  2020cites this paper
• Phosphodiesterase-4 enzyme as a therapeutic target in neurological disorders.

  2020cites this paper
• Moderate treadmill exercise improves spatial learning and memory deficits possibly via changing PDE-5, IL-1 β and pCREB expression.

  2020cites this paper
• Inhibition of PDE2 and PDE4 synergistically improves memory consolidation processes.

  2020cites this paper
• In Vivo Plasticity at Hippocampal Schaffer Collateral-CA1 Synapses: Replicability of the LTP Response and Pharmacology in the Long-Evans Rat

  2020cites this paper
• Phosphodiesterase as a Target for Cognition Enhancement in Schizophrenia.

  2020cites this paper
• AMPA Induces NO-Dependent cGMP Signals in Hippocampal and Cortical Neurons via L-Type Voltage-Gated Calcium Channels.

  2019cites this paper
• The Implication of Androgens in the Presence of Protein Kinase C to Repair Alzheimer’s Disease-Induced Cognitive Dysfunction

  2019cites this paper
• Cryo-EM structure of phosphodiesterase 6 reveals insights into the allosteric regulation of type I phosphodiesterases

  2019cites this paper
• Advances in Discovery of PDE10A Inhibitors for CNS-Related Disorders. Part 2: Focus on Schizophrenia.

  2019cites this paper
• Phosphodiesterase expression in the normal and failing heart.

  2019cites this paper
• Applications of Neuroimaging Biomarkers in CNS Drug Development

  2019cites this paper
• Loss of Function of Phosphodiesterase 11A4 Shows that Recent and Remote Long-Term Memories Can Be Uncoupled.

  2019influential citation
• Pharmacological manipulation of cGMP and NO/cGMP in CNS drug discovery.

  2019cites this paper
• Design, synthesis of novel purin-6-one derivatives as phosphodiesterase 2 (PDE2) inhibitors: The neuroprotective and anxiolytic-like effects.

  2019cites this paper
• TAK-915, a Phosphodiesterase 2A Inhibitor, Ameliorates the Cognitive Impairment Associated with Aging in Rodent Models.

  2019cites this paper
• Target Engagement of a Phosphodiesterase 2A Inhibitor Affecting Long-Term Memory in the Rat

  2019cites this paper
• Phosphodiesterase Inhibitors: A Therapeutic Augmentation for Treatment of Cognitive Impairment

  2019cites this paper
• Compartmentalized cAMP Generation by Engineered Photoactivated Adenylyl Cyclases.

  2019cites this paper
• Phosphodiesterases, 3',5'-cyclic nucleotide (PDEs) (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database

  2019cites this paper
• Targeting Phosphodiesterases—Towards a Tailor-Made Approach in Multiple Sclerosis Treatment

  2019cites this paper
• Indole acids as a novel PDE2 inhibitor chemotype that demonstrate pro-cognitive activity in multiple species.

  2018cites this paper
• Phosphodiesterase Inhibitors in Object Recognition and Object Location Memory Tests

  2018cites this paper
• Current Therapeutic Targets for Alzheimer's Disease

  2018cites this paper
• HITS-CLIP in various brain areas reveals new targets and new modalities of RNA binding by fragile X mental retardation protein

  2018cites this paper
• Cyclic nucleotide phosphodiesterases: potential therapeutic targets for alcohol use disorder

  2018cites this paper
• Betulinic acid, a natural PDE inhibitor restores hippocampal cAMP/cGMP and BDNF, improve cerebral blood flow and recover memory deficits in permanent BCCAO induced vascular dementia in rats

  2018cites this paper
• The phosphodiesterase 5 inhibitor, KJH‐1002, reverses a mouse model of amnesia by activating a cGMP/cAMP response element binding protein pathway and decreasing oxidative damage

  2018cites this paper
• Identification of a Potent, Highly Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor Clinical Candidate.

  2018cites this paper
• Expression and localization of phosphodiesterase 2A in the submandibular gland of mice.

  2018cites this paper
• Phosphodiesterase 2A as a therapeutic target to restore cardiac neurotransmission during sympathetic hyperactivity.

  2018cites this paper
• A continual trials approach to recognition memory in mice

  2018cites this paper
• Discovery of novel purine nucleoside derivatives as phosphodiesterase 2 (PDE2) inhibitors: Structure-based virtual screening, optimization and biological evaluation.

  2018cites this paper
• Multicolour optogenetics for studying the roles of cAMP and cGMP in synaptic plasticity and memory

  2018influential citation
• Structure-Guided Design and Procognitive Assessment of a Potent and Selective Phosphodiesterase 2A Inhibitor.

  2018cites this paper
• Memory enhancing effects of BPN14770, an allosteric inhibitor of phosphodiesterase-4D, in wild-type and humanized mice

  2018cites this paper
• Involvement of Phosphodiesterase 2A Activity in the Pathophysiology of Fragile X Syndrome.

  2018cites this paper
• Phosphodiesterase 2A Inhibitor TAK-915 Ameliorates Cognitive Impairments and Social Withdrawal in N-Methyl-d-Aspartate Receptor Antagonist–Induced Rat Models of Schizophrenia

  2018influential citation
• Investigation of an 18F-labelled Imidazopyridotriazine for Molecular Imaging of Cyclic Nucleotide Phosphodiesterase 2A

  2018cites this paper
• The Phosphodiesterase 9 Inhibitor PF‐04449613 Promotes Dendritic Spine Formation and Performance Improvement after Motor Learning

  2018influential citation
• Targeting the NO/cGMP/CREB Phosphorylation Signaling Pathway in Alzheimer’s Disease

  2018cites this paper
• Uncovering the Signaling Pathway behind Extracellular Guanine-Induced Activation of NO System: New Perspectives in Memory-Related Disorders

  2018influential citation
• Novel Phosphodiesterase Inhibitors for Cognitive Improvement in Alzheimer's Disease.

  2018cites this paper
• Phosphodiesterase inhibition and modulation of corticostriatal and hippocampal circuits: Clinical overview and translational considerations

  2018cites this paper
• Advances in Discovery of PDE10A Inhibitors for CNS-Related Disorders. Part 1: Overview of the Chemical and Biological Research.

  2018cites this paper
• Surface Binding Energy Landscapes Affect Phosphodiesterase Isoform-Specific Inhibitor Selectivity

  2018influential citation
• Phosphodiesterase 2 inhibition preferentially promotes NO/guanylyl cyclase/cGMP signaling to reverse the development of heart failure

  2018cites this paper
• Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer’s disease

  2017cites this paper
• Pharmacological Rescue of Long-Term Potentiation in Alzheimer Diseased Synapses

  2017cites this paper